INDICATION: QUZYTTIR is indicated for the treatment of acute urticaria in adults and children 6 months of age and older. Limitations of Use: QUZYTTIR is not recommended in pediatric patients <6 years of age with impaired renal or hepatic function.

See if QUZYTTIR may be right for your patients

Actor portrayals of a female healthcare practitioner speaking with two female patients who appear to be mother and daughter Actor portrayals of a female healthcare practitioner speaking with two female patients who appear to be mother and daughter Actor portrayals.

Meet two potential patients who may benefit from QUZYTTIR treatments

Robert

  • 65 years old
  • Receiving rituximab infusion for treatment of chronic lymphocytic leukemia (CLL)
  • Pre-medicated with intravenous diphenhydramine (IV DPH)* and acetaminophen (APAP)
  • Past medical history: Depression and mild cognitive impairment
  • Medications: fluoxetine, zolpidem

90 minutes into his infusion, Robert experiences an acute allergic reaction (urticaria and flushing).

In clinical trials with cetirizine hydrochloride oral tablets, 186 patients were 65 years and older, and 39 patients were 75 years and older. No overall differences in safety were observed between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out.1

With regard to efficacy, the clinical trials did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently to QUZYTTIR than younger patients.

Actor portrayal of male, middle-aged patient with glasses and a dark gray shirt
Actor portrayal.

Maria

  • 33 years old
  • Receiving rituximab infusion for treatment of rheumatoid arthritis (RA)
  • Pre-medicated with intravenous diphenhydramine (IV DPH),* acetaminophen (APAP) and IV methylprednisolone
  • Past medical history: Depression
  • Medications: Fluoxetine
  • Lifestyle: Full-time employee, part-time college student

90 minutes into her infusion, Maria experiences an acute allergic reaction (urticaria and flushing).

Actor portrayal of young female patient with a grey collared shirt
Actor portrayal.

APAP=N-acetyl-para-aminophenol.

  • * Patients in the QUZYTTIR phase 3 study were excluded if they had taken a histamine-1 (H1) or histamine-2 (H2) antagonist within the past two hours.

When considering treatment for acute urticaria in specific patient types, QUZYTTIR may be an option1

Icon of a teddy bear with a stethoscope around its neck

Pediatrics†

Safety and efficacy established in patients 6 months to 17 years of age.

QUZYTTIR is not recommended in pediatric patients <6 years of age with impaired renal or hepatic function.

Icon of a geriatric patient with a cane

Geriatrics

In clinical trials with QUZYTTIR, 18 patients were 65 years and older, and 6 patients were 75 years and older. No overall differences in safety were observed between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

With regard to efficacy, the clinical trials did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently to QUZYTTIR than younger patients.

Icon of liver and kidneys

Renal and hepatic impairment‡

No dosage adjustments in patients with moderate and severe renal impairment and in patients on dialysis. No dosage adjustment in patients with hepatic impairment.

QUZYTTIR is not recommended in pediatric patients <6 years of age with impaired renal or hepatic function.

Icon of heart with an EKG wave in the center

Cardiac concerns‡

In four clinical studies in healthy adult males, there was no clinically significant increase in QTc, including in combination with erythromycin, ketoconazole, and azithromycin.

  • †Based on an extrapolation of data from the phase 3 pivotal trial with adult patients, pharmacokinetic data, and studies/cases of oral cetirizine use in pediatric patients.
  • ‡Based on studies with the oral formulation of cetirizine, the active ingredient in QUZYTTIR.
Icon of a handshake
Request a representative

Get more information about QUZYTTIR and resources available to support your patients.

Request a rep
×

Healthcare Professionals

The information contained in this section of the site is intended for US Healthcare Professionals only. Click Continue if you are a US Healthcare Professional.

Continue Cancel